OBJECTIVES: No head-to-head clinical trial has compared the efficacy of adalimumab versus etanercept as first-line therapy for patients with psoriatic arthritis (PsA). To bridge this gap, we implemented a matching-adjusted indirect comparison of adalimumab versus etanercept for PsA. METHODS: Using methodology developed by Signorovitch, patient-level data from the adalimumab randomized controlled trial (RCT) ADEPT were reweighted to match baseline characteristics from the pivotal published etanercept RCT. ADEPT patients were reweighted by their odds of enrollment in the etanercept trial, estimated using logistic regression model. Matched characteristics included demographics, baseline clinical measures, and concomitant treatment. After matching, biologic treatment arms were compared based on difference from placebo in percent achieving ≥20%, ≥50%, or ≥70% improvement in ACR criteria (ACR20/50/70), percent meeting PsA Response Criteria (PsARC), mean change in Health Assessment Questionnaire (HAQ), percent with ≥50%, ≥75%, or ≥90% improvement in PASI (PASI50/75/90), and change from baseline in modified total Sharp score (mTSS). Statistical significance was assessed using weighted Student’s t-tests. RESULTS: After reweighting, baseline characteristics were exactly matched across trials. Compared with etanercept-treated patients, adalimumab-treated patients had greater placebo-adjusted rates of ACR70 (23.9% vs. 7.9%), PASI50 (60.5% vs. 29.2%), PASI75 (55.0% vs. 19.5%), and PASI90 (40.2% vs. 2.8%) at Week 24 (all p<0.05). Adalimumab-treated patients also had greater change from baseline vs. placebo in mTSS (1.77 vs. 0.56, p=0.080) at Week 24 and greater rate of ACR70 (20.6% vs. 9.7%, p=0.055) at Week 12. No significant differences were found for ACR20, ACR50, PsARC, and HAQ change (all p>0.1). CONCLUSIONS: Matching-adjusted indirect comparison of adalimumab vs. etanercept in PsA finds that adalimumab treatment is associated with greater probability of ACR70, PASI50, PASI75, and PASI90 at Week 24.